Comprehensive Stock Comparison
Compare Regeneron Pharmaceuticals, Inc. (REGN) vs argenx SE (ARGX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ARGX | 78.6% revenue growth vs REGN's 1.0% |
| Value | REGN | Lower P/E (17.3x vs 25.6x) |
| Quality / Margins | REGN | 31.4% net margin vs ARGX's 23.3% |
| Stability / Safety | ARGX | Beta 0.44 vs REGN's 0.58, lower leverage |
| Dividends | REGN | 0.4% yield; 1-year raise streak; ARGX pays no meaningful dividend |
| Momentum (1Y) | ARGX | +22.8% vs REGN's +12.4% |
| Efficiency (ROA) | ARGX | 12.9% ROA vs REGN's 11.1%, ROIC -0.5% vs 12.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
argenx is a biotechnology company that develops antibody-based therapies for autoimmune diseases. It generates nearly all its revenue from VYVGART — its FcRn blocker for conditions like myasthenia gravis — with additional income from partnerships and licensing. The company's key advantage is its proprietary antibody engineering platform that creates differentiated therapies with potentially better safety and efficacy profiles.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
REGN leads in 2 of 6 categories (Financial Metrics, Valuation Metrics). ARGX leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 3.6x ARGX's $4.0B. REGN is the more profitable business, keeping 31.4% of every revenue dollar as net income compared to ARGX's 23.3%.
| Metric | REGNRegeneron Pharmac… | ARGXargenx SE |
|---|---|---|
| RevenueTrailing 12 months | $14.3B | $4.0B |
| EBITDAEarnings before interest/tax | $4.2B | $95M |
| Net IncomeAfter-tax profit | $4.5B | $923M |
| Free Cash FlowCash after capex | $3.2B | $213M |
| Gross MarginGross profit ÷ Revenue | +86.3% | +75.5% |
| Operating MarginEBIT ÷ Revenue | +25.7% | -1.0% |
| Net MarginNet income ÷ Revenue | +31.4% | +23.3% |
| FCF MarginFCF ÷ Revenue | +22.0% | +5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | +5.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.5% | +12.6% |
Valuation Metrics
At 18.8x trailing earnings, REGN trades at a 69% valuation discount to ARGX's 60.0x P/E.
| Metric | REGNRegeneron Pharmac… | ARGXargenx SE |
|---|---|---|
| Market CapShares × price | $107.6B | $47.5B |
| Enterprise ValueMkt cap + debt − cash | $91.4B | $46.0B |
| Trailing P/EPrice ÷ TTM EPS | 18.84x | 60.01x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.25x | 25.57x |
| PEG RatioP/E ÷ EPS growth rate | 2.98x | — |
| EV / EBITDAEnterprise value multiple | 21.64x | — |
| Price / SalesMarket cap ÷ Revenue | 7.50x | 21.67x |
| Price / BookPrice ÷ Book value/share | 2.72x | 9.09x |
| Price / FCFMarket cap ÷ FCF | 26.36x | — |
Profitability & Efficiency
ARGX delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $14 for REGN. ARGX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to REGN's 0.09x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs ARGX's 3/9, reflecting strong financial health.
| Metric | REGNRegeneron Pharmac… | ARGXargenx SE |
|---|---|---|
| ROE (TTM)Return on equity | +14.4% | +15.1% |
| ROA (TTM)Return on assets | +11.1% | +12.9% |
| ROICReturn on invested capital | +12.4% | -0.5% |
| ROCEReturn on capital employed | +10.8% | -0.4% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 3 |
| Debt / EquityFinancial leverage | 0.09x | 0.01x |
| Net DebtTotal debt minus cash | -$16.2B | -$1.5B |
| Cash & Equiv.Liquid assets | $18.9B | $1.5B |
| Total DebtShort + long-term debt | $2.7B | $39M |
| Interest CoverageEBIT ÷ Interest expense | 120.42x | 166.64x |
Total Returns (with DRIP)
A $10,000 investment in ARGX five years ago would be worth $22,521 today (with dividends reinvested), compared to $16,977 for REGN. Over the past 12 months, ARGX leads with a +22.8% total return vs REGN's +12.4%. The 3-year compound annual growth rate (CAGR) favors ARGX at 28.0% vs REGN's 1.1% — a key indicator of consistent wealth creation.
| Metric | REGNRegeneron Pharmac… | ARGXargenx SE |
|---|---|---|
| YTD ReturnYear-to-date | +0.8% | -8.7% |
| 1-Year ReturnPast 12 months | +12.4% | +22.8% |
| 3-Year ReturnCumulative with dividends | +3.4% | +109.5% |
| 5-Year ReturnCumulative with dividends | +69.8% | +125.2% |
| 10-Year ReturnCumulative with dividends | +104.7% | +3234.4% |
| CAGR (3Y)Annualised 3-year return | +1.1% | +28.0% |
Risk & Volatility
ARGX is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than REGN's 0.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 95.2% from its 52-week high vs ARGX's 82.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | REGNRegeneron Pharmac… | ARGXargenx SE |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.58x | 0.44x |
| 52-Week HighHighest price in past year | $821.11 | $934.62 |
| 52-Week LowLowest price in past year | $476.49 | $510.06 |
| % of 52W HighCurrent price vs 52-week peak | +95.2% | +82.1% |
| RSI (14)Momentum oscillator 0–100 | 49.1 | 33.9 |
| Avg Volume (50D)Average daily shares traded | 687K | 301K |
Analyst Outlook
Wall Street rates REGN as "Buy" and ARGX as "Buy". Consensus price targets imply 33.9% upside for ARGX (target: $1027) vs 9.7% for REGN (target: $857). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | REGNRegeneron Pharmac… | ARGXargenx SE |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $857.17 | $1026.71 |
| # AnalystsCovering analysts | 48 | 35 |
| Dividend YieldAnnual dividend ÷ price | +0.4% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $3.41 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +3.2% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 100 | 162.46 | +62.5% |
| argenx SE (ARGX) | 100 | 564.69 | +464.7% |
argenx SE (ARGX) returned +125% over 5 years vs Regeneron Pharmaceu… (REGN)'s +70%. A $10,000 investment in ARGX 5 years ago would be worth $22,521 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
| argenx SE (ARGX) | $15M | $2.2B | +14054.3% |
Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
| argenx SE (ARGX) | -145.3% | 38.0% | +126.2% |
Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
| argenx SE (ARGX) | -1.2 | 12.78 | +1165.0% |
Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021). argenx SE generated $-151M FCF in 2024 (+79% vs 2021).
REGN vs ARGX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is REGN or ARGX a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 18.8x trailing P/E (17.3x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — REGN or ARGX?
On trailing P/E, Regeneron Pharmaceuticals, Inc. (REGN) is the cheapest at 18.8x versus argenx SE at 60.0x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 17.3x.
03Which is the better long-term investment — REGN or ARGX?
Over the past 5 years, argenx SE (ARGX) delivered a total return of +125.2%, compared to +69.8% for Regeneron Pharmaceuticals, Inc. (REGN). A $10,000 investment in ARGX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARGX returned +32.3% versus REGN's +104.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — REGN or ARGX?
By beta (market sensitivity over 5 years), argenx SE (ARGX) is the lower-risk stock at 0.44β versus Regeneron Pharmaceuticals, Inc.'s 0.58β — meaning REGN is approximately 31% more volatile than ARGX relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — REGN or ARGX?
argenx SE (ARGX) is the more profitable company, earning 38.0% net margin versus 31.4% for Regeneron Pharmaceuticals, Inc. — meaning it keeps 38.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus -1.0% for ARGX. At the gross margin level — before operating expenses — ARGX leads at 89.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is REGN or ARGX more undervalued right now?
On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 17.3x forward P/E versus 25.6x for argenx SE — 8.3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARGX: 33.9% to $1026.71.
07Which pays a better dividend — REGN or ARGX?
In this comparison, REGN (0.4% yield) pays a dividend. ARGX does not pay a meaningful dividend and should not be held primarily for income.
08Is REGN or ARGX better for a retirement portfolio?
For long-horizon retirement investors, argenx SE (ARGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44)). Both have compounded well over 10 years (ARGX: +32.3%, REGN: +104.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between REGN and ARGX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.